BREAKING: Novo Nordisk says it will lower the U.S. list price of some of its insulin products by up to 75% starting Jan. 1, 2024, following a similar move by Eli Lilly.
The change — which will take effect on Jan. 1, 2024 — follows a similar move by Eli Lilly, whichthat it will lower the list price for several of its products, including Humalog, by 70% later this year.
“Novo Nordisk is playing follow the leader here, after Eli Lilly cut prices substantially on insulin products,” said Larry Levitt, the executive vice president for health policy at KFF, formerly known as the Kaiser Family Foundation. The price of Levemir, a long-acting insulin, will be reduced by 65% to $107.85 per vial and $161.77 per pen, the company said. Novolin will see a similar price reduction, at $48.20 per vial and $91.09 per pen.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk to lower prices of some insulins, following similar move by LillyNovo Nordisk said that it is lowering the prices of several insulin products by up to 75% starting in 2024. The company’s U.S.-listed shares were up about...
Read more »
Novo Nordisk Will Cut Insulin Cost in U.S. by Up to 75 PercentNovo Nordisk will slash the list price of several of its insulin drugs by as much as 75 percent, the company said Tuesday.
Read more »
Lilly Insulin Value Program | Lilly Insulin AffordabilityLilly is committed to helping people with diabetes get the medicine they need, regardless of whether you have commercial insurance or no insurance. Learn more about how Lilly may be able to help with potential cost saving solutions.
Read more »
WSJ News Exclusive | Novo Nordisk to Slash Insulin Prices by Up to 75%Breaking: Novo Nordisk, a large insulin maker, plans to cut the prices of its widely used products up to 75% to make them more affordable for patients. This follows a similar move by Eli Lilly.
Read more »
Novo Nordisk plans to cut insulin prices in U.S. by up to 75%Drugmaker Novo Nordisk said on Tuesday it would cut list prices for several insulin drugs by up to 75% in the United States, starting Jan. 1, 2024.
Read more »